Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Top Alliance Of 2016: Cast Your Vote!

Executive Summary

It's time once again for In Vivo's Deal of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)

In Vivo's Top Alliance Of 2016 – The Nominees Are:

Synthetic Bio Tie-Up: Synologic received big pharma validation of its technology in early February, signing its first-ever partnership, a multiyear collaboration with AbbVie Inc. to develop "synthetic biotic" therapies for Crohn's disease and ulcerative colitis. [See Deal]

Cigna Pays If PCSK9s Perform: In May, Cigna Corp. signed value-based contracts with Amgen Inc. and Sanofi/Regeneron Pharmaceuticals Inc. for their cholesterol-lowering drugs Repatha and Praluent. The drug makers will discount the products more steeply if LDL levels don't drop. (Also see "Cigna’s Bradbury Talks PCSK9 Contracts And Value Versus Volume" - Pink Sheet, 11 May, 2016.)

Verily We Roll Along: Google-owned Verily Life Sciences formed diabetes and neuromodulation joint ventures with big pharmas GlaxoSmithKline PLC (August) and Sanofi (September). [See Deal][See Deal]

AstraZeneca Drops Assets: In October, AstraZeneca PLC completed five out-licensing deals cumulatively worth more than $1bn, the busiest month by far in its year-long purge of non-core assets. [See Deal][See Deal][See Deal][See Deal][See Deal]

Bayer Buys Into Gene Editing: In August, Bayer AG and CRISPR Therapeutics AG unveiled their $335m joint venture Casebia Therapeutics, which will use CRISPR's gene editing technology to develop drugs for blood disorders, blindness and congenital heart disease. [See Deal]

CLICK HERE Here To Cast Your Vote For The Most Significant Strategic Alliance Of 2016

Coming Up Next In IVDOTY16: Top Financing And Top M&A

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC097901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel